IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genesYukihide Momozawa, Judy H. Cho, Leila Amininejad et al.|Nature Communications|2018Cited by 252
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Andrea E. van der Meulen‐de Jong et al.|Journal of Crohn s and Colitis|2019Cited by 183
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and FynMark Löwenberg, Daniël W. Hommes|Blood|2005Cited by 169
Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYNMark Löwenberg, Daniël W. Hommes|EMBO Reports|2006Cited by 150
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129